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MORC3 is linked to inflammatory myopathies and
cancer; however, the precise role of MORC3 in
normal cell physiology and disease remains poorly
understood. Here, we present detailed genetic,
biochemical, and structural analyses of MORC3.
We demonstrate thatMORC3 is significantly upregu-
lated in Down syndrome and that genetic abnormal-
ities in MORC3 are associated with cancer. The CW
domain of MORC3 binds to the methylated histone
H3K4 tail, and this interaction is essential for recruit-
ment of MORC3 to chromatin and accumulation in
nuclear bodies. We show that MORC3 possesses
intrinsic ATPase activity that requires DNA, but it is
negatively regulated by the CW domain, which inter-
acts with the ATPase domain. Natively linked CW
impedes binding of the ATPase domain to DNA, re-
sulting in a decrease in the DNA-stimulated enzy-
matic activity. Collectively, our studies provide a
molecular framework detailing MORC3 functions
and suggest that its modulation may contribute to
human disease.
INTRODUCTION
Microrchidia 3 (MORC3) is a member of the Morc family of four
proteins evolutionarily conserved throughout the eukaryotic
kingdom. MORC3, also called nuclear matrix protein 2 (NXP2),
was originally identified as a nuclear matrix-associated protein
with RNA-binding activity (Kimura et al., 2002). It is one of the
most common autoantigens present in inflammatory myopa-
thies, with one-fourth of juvenile dermatomyositis (DM) patients
being found positive for anti-MORC3 antibodies (Gunawardena
et al., 2009). Clinical studies reveal elevated MORC3 expression
in leukocytes following anti-cancer chemotherapy (Gonza´lez-
Ferna´ndez et al., 2012). MORC3 localizes to promyelocytic leu-Cell Report
This is an open access article under the CC BY-Nkemia nuclear bodies (PML-NBs), where it regulates p53 activity
essential for cellular senescence in human and mouse fibro-
blasts (Mimura et al., 2010; Takahashi et al., 2007). Accumulating
evidence suggests a role of MORC3 in transcription, because it
promotes gene silencing when bound to SUMO-2 (Rosendorff
et al., 2006).
MORC3 is a large, 939-residue multi-modular protein. It con-
tains an N-terminal gyrase, heat shock protein 90 (Hsp90), histi-
dine kinase, and MutL (GHKL)-type ATPase domain, which is
conserved in other human MORC family members (MORC1,
MORC2, and MORC4) and is present in a diverse array of chro-
matin-modified enzymes and chaperones (reviewed in Dutta and
Inouye, 2000; Li et al., 2013). Although the catalytic activity of
MORC3 has not been established, the ATP-hydrolyzing function
of orthologous and homologous Morc proteins was found to be
essential for heterochromatin condensation and gene silencing
inArabidopsis thaliana and for chromatin remodeling in response
to DNA damage in mammalian cells (Li et al., 2013; Moissiard
et al., 2012; Pastor et al., 2014). The ATPase domain in
MORC3 is followed by a CW-type zinc finger and a C-terminal
coiled-coil region. The MORC3 CW domain has been shown to
interact with histone H3 peptides (Li et al., 2012; Liu et al.,
2016); however, the functional significance of this interaction re-
mains unclear. The biological role of the coiled-coil region is un-
known, though it may mediate protein dimerization.
Reports have demonstrated that MORC3 is misregulated in
the brain of a Down syndrome (DS) mouse model (Ling et al.,
2014) and anti-MORC3 antibodies are found in most patients
with cancer-associated DM (Fiorentino et al., 2013), yet the pre-
cise role of MORC3 in normal cellular processes and in disease
has not been determined. Here, we present detailed genetic,
biochemical, and structural analyses of MORC3. We report on
histone H3K4me- and DNA-binding functions of MORC3, inter-
domain crosstalk, and intrinsic catalytic activity of this ATPase.
Our mechanistic and mutagenesis studies reveal an intricate
multivalent engagement of MORC3 with chromatin and regula-
tion of the ATPase activity by DNA and CW and suggest a
possible link between impaired MORC3 histone-binding activity
and disease.s 16, 3195–3207, September 20, 2016 ª 2016 The Author(s). 3195
C-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Figure 1. MORC3 Is Consistently Upregulated in Trisomy 21 Cells
(A) Box-and-whisker plots of MORC2, MORC3, and MORC4 expression levels across tissue types from the GTEx Portal.
(B–D) Box-and-whisker plots ofMORC3,MORC2, andMORC4 expression in D21 and T21 fibroblasts (B), lymphoblastoid cell lines (C), and patient monocytes
and T cells (D). The mRNA expression values are in RPKM. Benjamini-Hochberg adjusted p values were calculated using DESeq2.
(E) Venn diagram of differentially expressed genes in DS from human fibroblasts, human lymphoblastoids, and mouse brains.
See also Figure S1.RESULTS AND DISCUSSION
MORC3 Is Markedly Upregulated in DS
Because the MORC3 gene is encoded on chromosome 21
(chr21), trisomy of which causes DS, the most common chromo-
somal abnormality in humans, we examined whether MORC3
contributes to the disease pathology. We first analyzed and
compared expression ofMORC3 and two other family members,3196 Cell Reports 16, 3195–3207, September 20, 2016MORC2 and MORC4, which are located on chr22 and chrX,
respectively, using the Genotype-Tissue Expression (GTEx) Por-
tal. We found that all three genes are expressed ubiquitously
across tissues and to similar levels (Figure 1A). To determine
whetherMORC3 is subject to inter-individual and tissue-specific
variation, we next performed RNA sequencing (RNA-seq) on a
panel of 12 age- and gender-matched euploid (D21) and T21
fibroblasts and measured MORC3, MORC2, and MORC4
expression levels. We found that MORC3 is substantially upre-
gulated in T21 cells compared to D21 cells, and this discernible
upregulation is conserved across different individuals (Fig-
ure 1B). In contrast, MORC2 and MORC4 expression levels re-
mained unchanged in T21 and D21 cells.
To test whether MORC3 upregulation is conserved in a
different tissue, we carried out RNA-seq on a panel of six age-
matched female D21 and T21 lymphoblastoid cells. Like in fibro-
blasts, MORC3, but not MORC2, was upregulated in T21
lymphoblastoid cells relative to D21 cells (Figure 1C). MORC4
was also strongly upregulated in T21 lymphoblastoid cells; how-
ever, this upregulation appeared to be unique to these cell lines
and potentially confounded by the near lack of MORC4 expres-
sion in D21 cells. Finally, to examine MORC3 expression levels
in naive patient samples, we isolated monocytes and T cells
from 17 individuals (10 T21 and 7 D21), extracted RNA, and per-
formed RNA-seq. Analysis of the RNA-seq data revealed
consistent upregulation of MORC3, but not MORC2 or
MORC4, in individuals with T21 (Figure 1D). Furthermore, the
observed upregulation level of MORC3 was equal to or greater
than that of genes known to contribute to DS pathology,
including RCAN1, DYRK1A, APP, and RUNX1. For example, in
monocytes from individuals with T21, MORC3 is upregulated
to a greater extent (1.69-fold) than RCAN1 (1.36-fold), DYRK1A
(1.31-fold), APP (1.21-fold), and RUNX1 (0.86-fold). Altogether,
these results demonstrate the high expression level of MORC3
in cells from individuals with DS, which is conserved across
different tissue types.
To establish whether MORC3 upregulation is conserved
across species, we analyzed our RNA-seq datasets against a
published dataset of gene expression in brains of a mouse
Ts1Cje model of DS. The Ts1Cje model has a partial triplication
of the region of mouse chr16 that is syntenic to human chr21.
Notably, we found that although relatively few (15) genes are
consistently upregulated in the five datasets, MORC3 is among
them (Figure 1E). Such conservation of MORC3 upregulation
among individuals, tissues, and even species suggests that
MORC3 could be part of a core signaling cascade consistently
deregulated by trisomy 21.
Genetic Abnormalities in MORC3 Are Associated with
Cancer
A subset of DM patients has been reported to be at increased
risk of malignancies at the time of DM diagnosis (Fiorentino
et al., 2013; Madan et al., 2009). Because most patients with
cancer-associated DMpresent antibodies toMORC3 (Fiorentino
et al., 2013), we sought to characterize a possible link between
MORC3 and cancer. We performed a survey of genetic alter-
ations inMORC3 across human cancers collected in The Cancer
Genome Atlas (TCGA). MORC3 is altered (mutation, amplifica-
tion, or deletion) in multiple cancers, most frequently in bladder,
uterine, stomach, and lung cancers, as well as diffuse large B cell
lymphomas (Figure S1A). We further explored the impact of
these alterations on patient outcomes and found that patients
with amplifications ofMORC3 showed significantly poorer over-
all survival in sarcoma (p = 0.002, log rank test), acute myeloid
leukemia (p = 0.004, log rank test), stomach adenocarcinoma
(p = 0.013, log rank test), breast invasive carcinoma (p = 0.034,log rank test), and uterine corpus endometrial carcinoma
(p = 0.036, log rank test) (Figure S1B). A possible association
of MORC3 antibody-positive idiopathic inflammatory myopa-
thies and cancer has also been suggested (Ichimura et al.,
2012). Collectively, the genetic abnormalities found in DS, DM,
and cancer patients point to a physiological importance of
MORC3, yet our knowledge of its function at the molecular level
is limited.
Binding of MORC3-CW to the Histone H3 Tail Is
Modulated by PTMs
In an effort to better understand the mechanism of action of
MORC3, we carried out biochemical and structural analyses of
its functional modules: the CW domain and the ATPase domain
(Figure 2A).While the CWdomain ofMORC3was shown to asso-
ciate with the histone H3 tail (Li et al., 2012), its preference for
and regulation by posttranslational modifications (PTMs) have
not been characterized. To determine the specific binding part-
ner and assess the effect of PTMs on binding activity of
MORC3-CW, we tested the CW domain in a high-throughput
histone peptide microarray (Figures 2B–2D). A glutathione
S-transferase (GST) fusion of CW was incubated with a library
of 200 synthetic histone peptides containing known single
and combinatorial PTMs (lysine acetylation, lysine and arginine
methylation, arginine citrullination, and serine and threonine
phosphorylation) found in the core and variant histone pro-
teins (Tables S1 and S2). Microarray results showed that the
MORC3 CW domain recognizes N-terminal histone H3 peptides
but does not recognize H2A, H2B, or H4 peptides (Figure 2D).
The effect of single modifications on CW binding varied, with
methylation of H3K4 enhancing this interaction and methylation
or citrullination of H3R2, phosphorylation of H3T3 and H3T6, and
acetylation of H3K4 reducing it. The negative effect of PTMs was
essentially annulled when K4me3 was present on the same pep-
tide, suggesting that the MORC3 CW domain is capable of bind-
ing to H3K4me3, regardless of the presence of neighboring
marks.
To assess the extent of enhancement observed in the CW
binding to H3K4me, we produced 15N-labeled MORC3-CW
and examined it in 1H,15N heteronuclear single quantum coher-
ence (HSQC) titration experiments (Figure 2E). Addition of the
H3K4me3 peptide (aa 1–12 of H3) induced large chemical
shift changes in MORC3-CW, indicating direct interaction.
Throughout titration of the peptide, a number of crosspeaks cor-
responding to the free state of the protein disappeared, and
simultaneously, another set of resonances, corresponding to
the bound state, appeared. This pattern of chemical shift
changes indicates tight binding in a slow exchange regime on
the nuclear magnetic resonance (NMR) timescale. Titration of
the unmodified H3 peptide led to an almost identical pattern of
resonance changes, and the slow exchange regime again
pointed to a strong interaction and binding affinity in a lowmicro-
molar range. In agreement, dissociation constants (Kds) for the
complexes of MORC3-CW with the H3K4me3, H3K4me2,
H3K4me1, and H3K4me0 peptides were found to be 0.64,
0.67, 0.74, and 6.8 mM, respectively, as measured by intrinsic
tryptophan fluorescence (Figures 2F and 2G). These results
suggest that the MORC3 CW domain does not efficientlyCell Reports 16, 3195–3207, September 20, 2016 3197
Figure 2. MORC3-CW Binds to the Histone H3 Tail
(A) Architecture of MORC3.
(B) Representative scanned image of a peptide microarray hybridized with the GST-MORC3 CW domain. Red spots are bound MORC3. Green spots are an
internal printing control and are used to filter false negatives from quantified datasets (Rothbart et al., 2012).
(C) Scatterplot of relative signal intensities from two microarrays hybridized with the GST-MORC3 CW domain. Average signal intensities from quantified arrays
were normalized to the most intense series of peptide spots and plotted on a relative scale from 0 (weak binding) to 1 (strong binding). The correlation coefficient
was calculated by linear regression analysis using GraphPad Prism v.5.
(D) Normalized average microarray signal intensities measuring the interaction of the GST-MORC3 CW domain with the indicated histone peptides. Error rep-
resents ±SEM from two arrays.
(E) Superimposed 1H,15N HSQC spectra of MORC3-CW collected upon titration with H3K4me3 and H3K4me0 peptides (residues 1–12 of H3). Spectra are color
coded according to the protein-to-peptide molar ratio.
(F) Binding affinities of WT MORC-CW for the indicated histone peptides measured by tryptophan fluorescence.
(G) Representative binding curve used to determine the Kd values by fluorescence.
See also Tables S1 and S2.discriminate among the methylation states of H3K4, displaying
only a slight preference for H3K4me3 species over H3K4me2
or H3K4me1. Furthermore, although its binding affinity for
H3K4me0 is10-fold lower, it is still in the range of binding affin-
ities exhibited by most known epigenetic readers toward modi-
fied or unmodified histones (1–50 mM) (Musselman et al.,
2012). These data corroborate well with the results of the recent
study that reports 0.8 mM (measured by isothermal titration
calorimetry [ITC]) or 1.8 mM (by fluorescence polarization [FP])
binding affinity of the MORC3 CW domain for H3K4me3 and
an 8-fold decrease in the affinity of this domain for H3K4me0
(Liu et al., 2016).
Structural Basis for the Interaction of the MORC3 CW
Domain with H3K4me3
To elucidate the molecular mechanism for the recognition of
H3K4me3, we determined the crystal structure of the MORC33198 Cell Reports 16, 3195–3207, September 20, 2016CW domain bound to an H3K4me3 peptide to a 1.56 A˚ resolu-
tion (Figure 3; Table S3). The MORC3 CW domain has a
compact globular fold consisting of a double-stranded antipar-
allel b sheet and a 310-helical turn linked by a single zinc-
binding cluster (Figure 3A). The H3K4me3 peptide is bound
in an extended conformation. It forms a third antiparallel b
strand pairing with the b1 strand of the protein. Backbone
amides of the peptide residues R2, K4, and T6 form character-
istic b sheet hydrogen bonds with the backbone amides of
Gln408, Trp410, and Gln412 of the CW domain (Figure 3A).
The N-terminal amino group of the peptide residue A1 donates
two hydrogen bonds to the carbonyl groups of Pro430 and
Glu431, whereas the methyl group of A1 is bound in a hydro-
phobic pocket lined with Trp433 (Figure 3B). The CW:H3K4me3
complex is further stabilized through an extensive set of
intermolecular hydrogen bonds involving the side chains of
the peptide. The Q5 amide is hydrogen bonded to Thr409,
Figure 3. Molecular Basis for Recognition of
H3K4me3 and H3K4me1 by MORC3-CW
(A) Ribbon diagram of the MORC3 CW domain in
complex with the H3K4me3 peptide (yellow).
Dashed lines represent intermolecular hydrogen
bonds. The protein residues involved in the in-
teractions with A1, R2, K4me3, Q5, R8, and K9 of the
peptide are colored wheat, blue, salmon, light green,
pink, and brown, respectively.
(B) Surface cartoon of the CW domain, with the
histone peptide shown in the ribbon and stick.
(C) A 2Fo-Fc map was calculated and contoured at
1.0s as yellowmesh around themodel of the histone
peptide and gray mesh around Trp-groove residues.
(D) Overlay of the structures of the MORC3
CW:H3K4me3 and MORC3 CW:H3K4me1 com-
plexes.
(E) Zoom-in view of the superimposed K4me1- and
K4me3-binding grooves. Water molecules are
shown as red spheres.
See also Table S3.and T6 forms a polar contact with the indole nitrogen atom of
Trp410. The guanidino group of R8 is restrained through the
interaction with the side-chain amide of Gln408 and a salt
bridge with the carboxyl group of Asp424. Another hydrogen
bond is formed between the amino group of K9 and the
carboxyl group of Asp454, whereas T11 is hydrogen bonded
to a serine residue from the vector.
The fully extended side chain of K4me3 occupies an elongated
groove made of two aromatic residues and two negatively
charged residues (Figures 3A and 3B). The aromatic side chains
of Trp410 and Trp419 are positioned orthogonally to each other,
creating side walls of the V-shaped groove, whereas Glu450 and
Glu453 in the C-terminal loop of the CW domain make the
groove’s end wall. The positively charged trimethylammonium
group of K4 is locked through cation-p interactions with
Trp410 and Trp419 and through electrostatic interactions with
the negatively charged carboxylates of Glu453 and Glu450.Cell ReportNegatively Charged End-Wall
Residues Direct Selectivity of
MORC3-CW
Given that MORC3-CW is capable of tight
binding to either methylated form of
H3K4, we sought to obtain mechanistic
insight into this behavior by determining
the crystal structure of the CW domain in
complex with an H3K4me1 peptide (Fig-
ure 3D; Table S3). We found that the overall
structure of the CW:H3K4me1 complex is
almost identical to the structure of the
CW:H3K4me3 complex (Figure 3D). How-
ever, there is a significant difference in co-
ordination of K4me3 and K4me1 within the
binding groove that can help explain the
indifference of MORC3-CW toward the K4
methylation state. In particular, the mono-
methylammonium moiety is restrained via
two hydrogen bonds, formed with thecarboxylate of Glu453 and mediated by two highly ordered
water molecules (Figure 3E). These water molecules are absent
in the H3K4me3-binding pocket; moreover, their relative spaces
are occupied by the methyl groups in the trimethylammonium
moiety. The two additional hydrogen bonds observed in the
K4me1-binding pocket likely compensate for the energetic loss
in the hydrophobic and cation-p interactions, which contribute
to coordination of K4me3 to a higher degree. Although we
were unable to obtain the structure of the H3K4me2-bound
CW domain, based on the comparative analysis, we anticipate
that the dimethylammonium moiety is stabilized through a
single water-mediated hydrogen bond with Glu453. Altogether,
the structural data suggest that the ability of the MORC3 CW
domain to interact robustly with H3K4me3/me2/me1 is likely
due to the ability of the end-wall residue, Glu453, to facilitate
water-mediated hydrogen bonds with H3K4 in the low-methyl-
ation state.s 16, 3195–3207, September 20, 2016 3199
Figure 4. End-Wall Residues Control Selec-
tivity of MORC3-CW
(A) Alignment of the CW domain sequences: abso-
lutely, moderately, and weakly conserved residues
are colored red, yellow, and light purple, respec-
tively. The residues of MORC3-CW involved in
contact with each residue of histone H3 are indi-
cated by arrows. An asterisk indicates E453.
(B) Close-up view of the overlaid K4me3-binding
sites in MORC3 (wheat) and ZCWPW1 (gray).
(C) Binding affinities of the MORC3-CW mutants as
determined by intrinsic tryptophan fluorescence.
(D) Superimposed 1H,15N HSQC spectra of mutated
MORC3-CW, collected upon titration with the
H3K4me3 peptide. Spectra are color coded ac-
cording to the protein-to-peptide molar ratio.
(E) Close-up view of the overlaid K4me3-binding
sites in MORC3-CW (wheat) and PHD fingers of
JARID1A (cyan) and ING2 (purple).
(F) Superimposed 1H,15N HSQC spectra of KDM1B
CW, recorded as H3K4me2 was titrated in.
See also Figure S2.Alignment of the CW domain sequences demonstrates that
the two tryptophan residues in the histone-binding site are
conserved in several other CWdomains; however, the negatively
charged end-wall residue (Glu453 in MORC3) is not conserved
(Figure 4A). For example, Glu453 is replaced with an aromatic
tryptophan residue in the CWdomain of CWPW1 that associates
with H3K4me3 2.5-fold, 6-fold, and 14-fold tighter than it
associates with H3K4me2, H3K4me1, and H3K4me0, respec-
tively (Figure 4B) (He et al., 2010). To further corroborate the
importance of the end-wall residues in MORC3, we generated
a series of Glu453 mutants and assayed their interactions with
histone peptides by fluorescence spectroscopy and NMR. We
found that substitution of Glu453 with a tryptophan enhances
the preference of the MORC3 CW domain toward H3K4me3
(Figures 4C, 4D and S2).
The two-tryptophan V-shaped groove is also observed in
another reader of H3K4me, a plant homeodomain (PHD) finger
of JARID1A, which selects for the trimethylated mark (Wang
et al., 2009). While the tryptophan residues in the histone-
binding sites of JARID1A-PHD and MORC3-CW are superim-
posed well, the JARID1A-PHD finger’s groove does not have3200 Cell Reports 16, 3195–3207, September 20, 2016the end-wall residues and is fully open
ended (Figure 4E). On the other hand, a
number of H3K4me3-specific PHD fin-
gers, including ING2, contain an aromatic
residue in the end-wall position (Pen˜a
et al., 2006). Interestingly, PHD fingers
use the N-terminal loop preceding the
b sheet to create the end wall, whereas
the MORC3 CW domain uses the C-termi-
nal loop to form its end wall (Figure 4E).
Substitution of Glu453 in MORC3-CW
with a positively charged lysine residue
resulted in a 10-fold decrease in binding
to H3K4me3, indicating that electrostatic
repulsion between Lys453 and the posi-tively charged trimethylammonium group of K4 impedes
complex formation (Figures 4C and 4D). Similarly, a decrease
in binding was observed for the E453R mutant of MORC3-
CW (Figure S2). Altogether, our results indicate that the
end-wall residues in the binding site of the MORC3 CW
domain account for the ability of this domain to bind either
methylation state of H3K4. While the cation-p interactions
involving the aromatic Trp410 and Trp419 residues favor
trimethylated lysine over dimethylated or monomethylated
lysine, the negatively charged end-wall residues enhance
interaction with the low-methylation states by providing extra
water-mediated hydrogen bonds. Increased electrostatic
attraction forces with a less delocalized positive charge in the
low-methylation states of lysine would further strengthen this
interaction.
Tryptophan Residues Are Necessary for Binding of
MORC3-CW to H3K4me3
The critical role of the histone-binding site residues was sup-
ported by mutational analysis. We generated point mutants of
MORC3-CW, tested their stability and binding to H3K4me3
Figure 5. Critical Role of the Histone-Binding
Site Residues of MORC3-CW
(A) Binding affinities of the MORC3-CW mutants
as determined by tryptophan fluorescence (a) or
NMR (b).
(B) Superimposed 1H,15N HSQC spectra of the
MORC3-CW mutants, collected upon titration with
H3K4me3. Spectra are color coded according to the
protein-to-peptide molar ratio.
(C) Representative binding curves used to determine
the Kd values by NMR.
(D) Superimposed 1H,15NHSQC spectra ofMORC3-
CW, recorded as H3 peptide (residues T3–S10) was
titrated in.
See also Figures S3 and S4.using NMR, and assessed the strength of these interactions
by fluorescence spectroscopy and NMR (Figure 5). We found
that Trp410 and Trp419 in the Trp-groove do not contribute
equally to the interaction with H3K4me3. Substitution of
Trp410 with an alanine reduced the binding by two orders of
magnitude, whereas replacement of Trp419 with an alanine
decreased this interaction more severely, i.e., by three orders
of magnitude, and the Trp419Kmutant was completely impaired
in binding to H3K4me3 (Figures 5A and S3). The uneven contri-
bution probably reflects the fact that in the complex, the
K4me3 group is placed closer to Trp419 than to Trp410. The dis-
tance from the nitrogen atom in the trimethylammonium group to
the Cg atom of Trp410 is 4.9 A˚; however, the corresponding dis-
tance to Trp419 is 4.2 A˚, which is 0.7 A˚ shorter. Much like K4me3
in the MORC3-CW:H3K4me3 complex, the monomethylammo-
nium and ammonium moieties in the MORC3-CW:H3K4me1
and MORC3-CW:H3K4me0 complexes lie closer to Trp419,
though the complex with the unmodified H3 peptide crystallized
as a dimer with the histone-binding site being partially in
the dimeric interface, hence precluding us from carrying out
detailed analysis of the binding mechanism (Figure S4). Con-
current mutation of both Trp residues to alanine resulted in an
unfolding of the protein, which infers that these residues also
play a role in structural stability of the CW domain. Interestingly,
the CW domain of KDM1B, a demethylase that demethylates
H3K4me2/me1 (Ciccone et al., 2009), contains both tryptophan
residues (Figure 4A); however, NMR titration experiments
showed that the KDM1B CW domain does not interact with the
H3K4me2 peptide (Figure 4F). This suggests that for certain
CW domains, the presence of two Trp residues is necessary
but not sufficient for the binding.Cell ReportSubstitution of Asp407, Gln408, and
Gln412 residues that are involved in polar
contacts in some of the MORC3-CW com-
plexes had little effect on the interaction
with H3K4me3 (Figure 5A). However, bind-
ing of the Q408A/D424A mutant was
reduced 40-fold, pointing to the impor-
tant contribution of the salt bridge formed
between Asp424 and H3R8 to the interac-
tion. We also found that the first two resi-
dues of histone H3, A1 andR2, are requiredfor the interaction of the CW domain, because no binding was
detected to the peptide containing residues T3–S10 of histone
H3 (Figure 5D).
MORC3-CW Interacts with the ATPase Domain
Considering the proximity of CW to the ATPase domain, being
separated by about 12 residues in MORC3, we next asked
whether the two modules are in contact. We generated an iso-
lated ATPase domain of MORC3, purified the His-tag fusion
protein, and titrated it into an NMR sample containing 15N-
labeled MORC3-CW E453A (Figures 6A and S5). We used
His-tagged ATPase due to its solubility and the E453A mutant
and H3K4me0 peptide to avoid a slow exchange regime and
thus to be able to compare the patterns of resonance changes
in CW. Substantial chemical shift perturbations in CW E453A
and broadening and loss of signal intensities in 1H,15N trans-
verse relaxation optimized spectroscopy (TROSY) experiments
upon addition of His-ATPase indicated that the two domains of
MORC3 form a complex (50 kDa). Although the pattern of
resonance changes was distinctly different from the pattern
of resonance changes induced in MORC3-CW E453A by the
histone H3K4me0 peptide, many amides of CW were perturbed
by either ligand, suggesting that binding interfaces may
partially overlap or substantial conformational changes may
accompany these interactions (compare upper panels in Fig-
ure 6A). Thermodynamic parameters for the MORC3-CW
E453A:His-ATPase complex, obtained from ITC measure-
ments, revealed a 1:1 stoichiometry of the complex and a Kd
of 9 mM for the isolated, i.e., unlinked, domains (Figure 6B).
Clearly, this interaction should be tighter when the two domains
are physically linked.s 16, 3195–3207, September 20, 2016 3201
Figure 6. MORC3 Is an ATPase
(A) Superimposed 1H,15N TROSY (top left and bot-
tom row) spectra and 1H,15N HSQC spectra (top
right) of MORC3-CWE453A, collected upon titration
with indicated ligands. Spectra are color coded ac-
cording to the protein-to-ligand molar ratio.
(B) Representative ITC binding curves observed
for the interaction between MORC3 His-ATPase
and CW.
(C) Rate of ATP hydrolysis by MORC3 His-ATPase.
Error represents SD between at least three separate
experiments (two experiments for His-ATPase-CW
with DNA or H3 at 30C).
(D and E) EMSA with NCPs (D) or 601 DNA (E) in the
presence of increasing amounts of His-ATPase, as
described in Experimental Procedures.
(F) EMSAwith 601 DNA in the presence of increasing
amounts of His-ATPase-CW.
(G) Superimposed 1H,15N HSQC spectra of
MORC3-CW upon titration with 601 DNA.
(H) Model for the regulation of MORC3.
See also Figure S5.To establish the relationship between the two binding part-
ners of CW, we titrated the H3K4me0 peptide into the CW
E453A:His-ATPase (1:1 molar ratio) complex and collected
1H,15N TROSY spectra (Figure 6A, lower-left panel). An
appearance of the crosspeaks corresponding to the CW
E453A:H3K4me0 complex and simultaneous shifting of the
ATPase-perturbed resonances to their positions in the apo
state of CW suggested that the histone peptide displaces
the ATPase domain from the CW domain. Reverse titration of
the His-ATPase domain into the CW E453A:H3K4me0 (1:4)
complex led to the disappearance of some crosspeaks due
to formation of the large CW E453A:His-ATPase complex.
Although ATPase could not efficiently displace H3K4me0 at
this molar ratio of the interactors, small shifting of the his-
tone-perturbed resonances toward their positions in the apo3202 Cell Reports 16, 3195–3207, September 20, 2016state also suggested that the ATPase
domain disrupts the CW E453A:H3K4me0
complex. Collectively, these results indi-
cate that MORC3-CW has two binding
partners, H3 and the ATPase domain,
and that their binding sites at least
partially overlap.
MORC3 Possesses ATPase Activity
that Requires DNA
Previously, MORC2, a homolog ofMORC3,
was reported to have ATPase activity; how-
ever, this function in MORC3 has not been
evaluated. To determine whether the
GHKL-type ATPase domain of MORC3 is
capable of hydrolyzing ATP, we carried
out an assay that couples the release of
inorganic phosphate, produced by the
hydrolysis of ATP to ADP, to the enzy-
matic conversion of 2-amino-6-mercapto-
7-methylpurine ribonucleoside (MESG) bypurine nucleoside phosphorylase (PNP). This results in a shift
in the wavelength maximum absorbance from 330 nm for
MESG to 360 nm for the product. Following incubation of the
MORC3 His-ATPase domain with ATP, MESG, and PNP, the
release of inorganic phosphate was quantified by measuring an
increase in the absorbance at 360 nm. As shown in Figure 6C,
the His-ATPase domain of MORC3 hydrolyzed ATP with a rate
of 0.47 ± 0.03 mmol min1 at 22C. The rate of ATP hydrolysis
was increased to 0.77 ± 0.06 mmol min1 in the presence of
14-mer double stranded DNA (dsDNA) in the reaction and to
0.80 mmol min1 in the presence of a mixture of mononucleo-
somes and dinucleosomes. A similar 2-fold increase in enzy-
matic activity was observed at 30C, and an 3-fold increase
was detected with Widom 601 (147 bp) DNA. These data
demonstrate that the ATPase activity is an intrinsic function of
Figure 7. CW Domain Is Required for the
Recruitment of MORC3 to Chromatin
(A) Chromatin association assays for FLAG-tagged
MORC3 (WT) or the indicated mutants from asyn-
chronously growing HeLa cells. Mock, no DNA
control.
(B) Representative confocal microscopy images of
FLAG-tagged WT and mutant forms of MORC3 in
HeLa cells. Scale bars, 10 mm.
See also Figure S6.MORC3,which is enhanced in the presence of either free or chro-
matinized DNA.
To assess whether the ATPase domain directly binds DNA, we
used electrophoretic mobility shift assays (EMSAs). Increasing
amounts of His-ATPase were incubated with Widom 601 DNA
or reconstituted nucleosome core particles (NCPs), and the re-
action mixtures were resolved on a 5% native polyacrylamide
gel (Figures 6D and 6E). A gradual increase in MORC3 His-
ATPase concentration in the assays resulted in a shift of the
DNA and/or NCP bands, indicating direct interaction of the
ATPase domain with either free or nucleosomal DNA.
CW Negatively Regulates DNA-Dependent ATPase
Activity
Because the CW and ATPase domains physically interact, we
examined whether the CW domain modulates the ATPase ac-
tivity of MORC3. We generated a MORC3 construct harboring
linked ATPase and CW domains and tested it in the ATPase
assay (Figure 6C). We found that although the linked CW
domain has little negative effect on the intrinsic catalytic activity
of the ATPase domain, it considerably decreased the rate of
hydrolysis in the presence of DNA. Modeling of the MORC3
ATPase domain structure suggests highly positively chargedCell Reportsurface potential (data not shown), which
likely allows this domain to bind negatively
charged DNA. Because the CW domain,
and particularly its H3-binding site, is
highly negatively charged, we hypothe-
sized that binding of CW to the ATPase
domain precludes binding of the ATPase
to DNA. Indeed, EMSA experiments with
601 DNA showed that the DNA-binding
function of His-ATPase-CW of MORC3 is
impaired (Figure 6F). Of note, the CW
domain itself does not bind DNA, because
no significant chemical shift perturba-
tions were detected in the 1H,15N HSQC
spectra of 15N-labeled MORC3-CW when
601 DNA was titrated in (Figure 6G). Addi-
tion of the H3 peptide to His-ATPase-CW
led to a slight increase in the rate of hy-
drolysis, suggesting that binding of CW
to H3 could release the ATPase domain
from CW and enhance its catalytic activity
(Figure 6C). Overall, these results suggest
that CW negatively regulates the DNA-dependent MORC3 ATPase activity, likely through hindering
DNA binding of the ATPase domain (Figure 6H).
Histone Binding Function Is Essential for the
Recruitment of MORC3 to Chromatin and Accumulation
in Nuclear Bodies
Our findings suggest that MORC3 is capable of engaging chro-
matin viamultivalent contacts. To determinewhether the interac-
tion of MORC3-CW with H3 is necessary to recruit MORC3 to
chromatin in vivo, we investigated cellular localization of FLAG-
tagged full-length MORC3 in HeLa cells using chromatin associ-
ation assays (Figure 7A). Both wild-type (WT) MORC3 and
mutants carrying mutations in the CW domain that either disrupt
the CW structure (C416S and C416A) or abrogate binding to the
histone H3 tail (W419A) were tested. Cells were harvested by
trypsinization 48 hr after transfection, and FLAG-MORC3 in
biochemically separated chromatin and soluble fractions was
examined by immunoblotting. Chromatin fractionation experi-
ments revealed that WT FLAG-MORC3 purifies in the chromatin
and soluble fractions, but MORC3 mutants impaired in H3 bind-
ing did not associate with chromatin and were found only in the
soluble fractions. These data demonstrate that interaction with
H3 is necessary and sufficient for MORC3 to retain on chromatin.s 16, 3195–3207, September 20, 2016 3203
MORC3 was previously shown to concentrate in nuclear
bodies (NBs) (Mimura et al., 2010; Takahashi et al., 2007). To
define the role of the CW domain in this function, HeLa cells
were transfected with 33 FLAG-MORC3 transgenes, and 48 hr
after transfection, FLAG-tagged proteins were visualized using
anti-FLAG antibodies by confocal fluorescence microscopy. As
shown in Figure 7B, WT FLAG-MORC3 was found localized to
NBs; however, FLAG-MORC3 W419A and FLAG-MORC3
C416A mutants that are unable to bind histones diffused
throughout the nucleus. Collectively, these results underscore
a direct link between the histone binding of MORC3 through its
CW domain and the function of MORC3 as a chromatin-associ-
ated ATPase and a NB factor.
Some Cancer-Relevant Mutations Decrease Binding of
MORC3-CW to H3
To date, 168 cancer-relevant aberrations, including mutations,
reading frameshifts, and deletions, have been identified in
MORC3, 7 of which reside in the CW domain (Figure S6A,
cBioPortal). In particular, MORC3-CW R420Q mutation is found
in multiple cancer types, such as prostate and stomach cancers
and melanoma. To determine whether the cancer-related muta-
tions affect binding of MORC3 to H3, we generated Q408H,
R420Q, D424H, P430S, D440Y, R444G, and P449R mutants of
MORC3-CW found in breast, prostate, cervical, stomach, mela-
noma, liver, and lung cancers and glioblastoma and tested the
corresponding 15N-labeled proteins by NMR (Figure S6). We
found that while all mutants were stable, binding of R420Q and
Q408H to H3K4me3, compared to WT, was decreased 200-
fold and 80-fold, respectively, whereas binding of D424H
was slightly reduced and P430S, D440Y, R444G, and P449R
were able to associate with H3K4me3 as strongly as theWT pro-
tein (Figures S6D and S6E).
Mapping the cancer-relevant mutations on the structure of
the CW:H3K4me3 complex reveals that some of the mutated
residues are positioned to either mediate a proper fold of the
domain or make contact with the histone peptide. For example,
three hydrogen bonds formed between the guanidino group
of Arg420 and the backbone carbonyls of Asn445, Val448, and
Pro449 bridge the C-terminal loop, which contains the end-
wall residues, to the core of the CW domain. Mutating Arg420
to a glutamine would result in a loss of these bonds andmay sub-
sequently yield an incorrect conformation of the C-terminal loop.
Both Gln408 and Asp424 are involved in the interactions with
the side chain of histone H3R8, and as we anticipated, mutations
of these residues led to a decrease in histone binding of the
CW domain. Altogether, our structural and mutational analyses
demonstrate that two of the seven cancer-relevant mutants of
MORC3-CW have compromised histone-binding activity—and
thus suggest a possible relationship between this function of
MORC3 and the disease.
Conclusions
In this work, we present comprehensive genetic, biochemical,
and structural analyses of MORC3. We show that MORC3 is
markedly upregulated in DS across different individuals, tissues,
and species and that genetic abnormalities inMORC3 are asso-
ciated with cancer. Overexpression of MORC3 in multiple T213204 Cell Reports 16, 3195–3207, September 20, 2016experimental systems is particularly notable, because few (15)
genes (Figure 1E) display conserved changes across our data-
sets. Other genes in this conserved group, including IFNAR1,
IFNAR2, andHMGN1, have previously been implicated in DS pa-
thology (Hallam and Maroun, 1998; Lane et al., 2014; Maroun
et al., 2000; Sullivan et al., 2016). Although we do not yet know
the exact roleMORC3 plays in DS, the consistency of its upregu-
lation is conspicuous and merits further investigation.
At the molecular level, we determined the structural mecha-
nism by which MORC3-CW recognizes the histone H3 tail. This
distinctive mechanism provides an explanation for the ability of
MORC3 to robustly interact with trimethylated, dimethylated,
or monomethylated H3K4 species. Interestingly, MORC3-CW
binds to unmodified histone H3, although 10-fold weaker, but
still with the appreciable binding affinity of 6.8 mM, which is
somewhat uncommon for an H3K4me-targeting reader, and a
similar 8-fold decrease in the binding affinity and a Kd of
14.6 mMhave also been reported by Liu et al. (2016). Association
of readers with the N terminus of the histone H3 tail is oftenmedi-
ated bymethylation of H3K4 (Musselman andKutateladze, 2011;
Musselman et al., 2012). Readers that possess an aromatic
cage, such as PHD fingers or double chromodomains, recognize
H3K4me3 but bind more weakly to H3K4me0. Conversely, bind-
ing of the H3K4me0-specific readers, including ADD domains
and some PHD fingers, to the histone tail is substantially
compromised or blocked by trimethylation of H3K4. The differ-
ence in binding affinities for H3K4me3 versus H3K4me0 can
be as high as three orders of magnitude. In this context, the
MORC3 CW domain represents a distinctive H3K4me reader
that uses its aromatic cage to affix lysine 4 irrespective of
its methylation state, reverberating a H3K9me reader, the
SAWADEE domain, that does not differentiate among the
methylation states and binds H3K9me3/me2/me1 with a similar
affinity of 2 mM (Law et al., 2013). Structural analysis of the
MORC3-CW complexes with trimethylated, monomethylated,
and unmodified H3K4 peptides reveals that this ability is due
to the presence of the negatively charged residues in the end-
wall position of the H3K4-binding aromatic groove of MORC3-
CW. The end-wall residues augment interaction with the
low-methylation states by providing additional water-mediated
hydrogen bonds and increasing electrostatic attraction forces.
It will be essential in future studies to establish whether the ability
of MORC3 to recognize H3K4me3/me2/me1 tails almost equally
well and, to a lesser extent, unmodifiedH3 plays a role in promot-
ing binding and/or stabilization of this ATPase at various
genomic regions enriched in these marks, including active,
repressed, or condensed chromatin.
We found that the ATPase and CW domains interact and that
MORC3 has intrinsic ATPase activity that is enhanced by DNA.
Direct linking of CW to the ATPase domain results in a decrease
in ATPase stimulation by DNA, which is likely a result of CW hin-
dering the ATPase domain from engaging with DNA. A similar
autoinhibition mode through blocking of DNA- or RNA-binding
sites of ATPase motors by chromodomains and other domains
have been reported for Chd1, CHD4, and Dbp5 ATPases
(Hauk and Bowman, 2011; Hauk et al., 2010; Narlikar et al.,
2013; Watson et al., 2012). In the case of Chd1, a negatively
charged a helix of the double chromodomains packs between
two halves of the ATPase domain, blocking binding of DNA, and
this inhibition can be relieved by nucleosomes, possibly through
engagement of CHD1 regions outside chromodomains (Hauk
et al., 2010).
What is the mechanism for the release of the MORC3 ATPase
inhibition? Although in-depth investigation is required to fully un-
derstand this mechanism, our current model suggests that the
negative regulatory function of CW and inhibition of the ATPase
catalytic activity could be alleviated through binding of the CW
domain to histone H3. A similar control of catalytic function by a
reader domain has been reported for the histone demethylase
KDM5A:bindingof the first (PHD1) finger of KDM5A to the histone
H3K4me0 tail stimulates activity of the neighboring demethylase
domain (Torres et al., 2015). Another example is the de novoDNA
methyltransferase DNMT3A that contains an ADD domain
(a reader specific for H3K4me0) next to the catalyticmethyltrans-
ferase domain. An elegant structural study has demonstrated
that DNMT3A exists in an autoinhibitory form, in which the ADD
domain interacts with and impedes enzymatic function of the
catalytic domain through blocking its DNA-binding activity (Guo
et al., 2015). Binding of ADD to H3K4me0, but not H3K4me3,
disrupts the ADD-catalytic domain complex, resulting in a large
rearrangement of ADD with respect to the catalytic domain and
stimulation of the enzymatic activity (Guo et al., 2015).
Our cell data demonstrate that binding of the CW domain to
histone H3 is required for the recruitment of MORC3 to chro-
matin and localization to NBs. Given the high sequence similarity
between MORC3 and MORC4 and that the CW domains of both
proteins recognize H3K4me (Liu et al., 2016), it is likely that the
chromatin-binding mode and the regulatory crosstalk of the
reader (CW) and the catalytic domain (ATPase) are conserved
in MORC4. However, the CW domains of MORC1 and
MORC2, the other two human MORC proteins, lack one of the
aromatic groove residues (W410 in MORC3) (Figure 4A) and do
not interact with histone H3. This inability to bind H3 suggests
that the mechanisms for chromatin engagement and regulation
of MORC1 and MORC2 are distinctly different from that of
MORC3. Considering that the MORC proteins are evolutionarily
conserved and that deregulation of MORCs is associated with
various disease states, it is imperative to elucidate and compare
such mechanisms. Understanding how MORC proteins engage
and modify chromatin at the molecular level could provide
insight into the cellular function of this family of ATPases.
EXPERIMENTAL PROCEDURES
Cell Culture and RNA-Seq
Fibroblasts were obtained from the Coriell Cell Repository and cultured in
DMEM with 10% fetal bovine serum (FBS). Lymphoblastoids were obtained
from the Nexus BioRepository and cultured in DMEM with 10% FBS. HeLa
were obtained from ATCC and cultured in DMEM with 10% FBS and 13 peni-
cillin/streptomycin. Total RNA was harvested from 5 3 106 cells using the
QIAGEN RNeasy kit per manufacturer’s instructions, including on-column
DNase digestion. Then, 500 ng of RNA were used to prepare sequencing li-
braries using the Illumina TruSeq mRNA Library Prep Kit. Libraries were
sequenced with Illumina HiSeq2000.
Statistical Analysis
Data quality control was performed using FastQC (v.0.11.2). Reads were
aligned to GRCh37/hg19 with Tophat2 (v.2.0.13), and high-quality mappedreads (MAPQ > 10) were filtered with SAMtools (v.0.1.19). Gene level counts
used for the reads per kilobase per million (RPKM) calculation were obtained
with HTSeq (v.0.6.1), and differential expression was determined with
DESeq2 (v.1.6.3), as described (Sullivan et al., 2016). Read counts were
modeled with a negative binomial distribution and normalized for library
size using the geometric mean. Dispersions were modeled with the empirical
Bayes method, and fold changes were calculated. Significance was calcu-
lated using a Wald test to generate p values, and multiple hypothesis correc-
tion was performed using the Benjamini-Hochberg method to generate
adjusted p values.
Isolation of Monocytes and T Cells by Florescence-Activated Cell
Sorting
Peripheral blood was collected in EDTA vacutainer tubes from ten T21
patients and seven D21 controls. Blood was centrifuged at 500 rcf for
15 min to separate plasma, buffy coat, and red blood cells (RBCs). Peripheral
blood mononuclear cells (PBMCs) were isolated from the buffy coat
fraction by RBC lysis and 13 PBS wash according to manufacturer’s instruc-
tions (Becton Dickinson, 555899). After RBC lysis and PBS wash, PBMCs
were stained for sorts at 10 3 107 to 20 3 107 cells/ml and then diluted to
approximately 5 3 107 cells/ml in flow cytometry sorting buffer (13 PBS,
1 mM EDTA, 25 mM HEPES [pH 7.0], 1% FBS). All staining was performed
in flow cytometry sorting buffer with fluorochrome-conjugated antibodies
for at least 15 min on ice while protected from light. Single-cell suspensions
were stained with CD45 (eBioscience, HI30), CD14 (BioLegend, 63D3),
CD3 (BioLegend, OKT3), CD 16 (BioLegend, B73.1), CD19 (BioLegend,
HIB19), CD56 (BioLegend, 5.1H11), and CD34 (BioLegend, 561) antibodies.
CD45+CD14+CD19CD3CD56 monocytes and CD45+CD3+CD14
CD19CD56 T cells underwent florescence-activated cell sorting (FACS)
into (13 DMEM supplemented with 4.5 g/L D-glucose, L-glutamine, and
5% FBS) on the MoFlo Astrios (Beckman Coulter) at the University of
Colorado School of Medicine Cancer Center Flow Cytometry Shared
Resource.
Protein Expression and Purification
The human MORC3 CW domain (aa 401–455 and 407–455) was cloned into a
pGEX 6p-1 vector. MORC3 ATPase (aa 1–392) and ATPase-CW (aa 1–455)
constructs were cloned into a pET28a vector. Unlabeled and uniformly
15N-labeled proteins were expressed in Rosetta2 (DE3) pLysS in Luria broth
(LB) or minimal media supplemented with 15NH4Cl (and 50 mM ZnCl2 for
CW). Protein expression was induced with 0.5 mM isopropyl b-D-1-thiogalac-
topyranoside (IPTG) for 16 hr at 18C. The His-ATPase and His-ATPase-CW
proteins were purified on Ni-NTA agarose beads (QIAGEN). The protein-bound
beads were washed at least three times with a 10 mM HEPES (pH 7.4) buffer,
containing 500 mM NaCl and 20 mM imidazole, and the His-tagged proteins
were eluted with a 10 mM HEPES (pH 7.4) buffer, containing 300 mM NaCl
and 200 mM imidazole. The GST-CW proteins were purified on glutathione
Sepharose 4B beads (GE Healthcare) in 50 mM sodium phosphate (pH 6.8)
buffer, supplemented with 100 mM NaCl and 2 mM DTT. The GST tag was
cleaved overnight at 4C with PreScission protease. Unlabeled proteins
were further purified by size exclusion chromatography and concentrated in
Millipore concentrators. All mutants were generated by site-directedmutagen-
esis using the Stratagene QuikChange mutagenesis protocol, grown and
purified as WT proteins.
NMR Experiments
NMR experiments were carried out on Varian INOVA 500, 600, and 900 MHz
spectrometers. The 1H,15N HSQC and 1H,15N TROSY spectra of 0.1 mM uni-
formly 15N-labeled WT or mutated MORC3-CW (or KDM1B CW) were re-
corded at 298 K. Experiments with the ATPase domain (Figures 6A and
S5) were performed in 10 mM HEPES (pH 7.4) buffer, supplemented with
100 mM NaCl, 1 mM TCEP, and 7% D2O, whereas all other NMR titration ex-
periments with CW were performed in 50 mM phosphate (pH 6.8) buffer,
supplemented with 100 mM NaCl, 2 mM DTT, and 7% D2O. Binding was
characterized by monitoring chemical shift changes in the proteins induced
by histone peptides (synthesized by the University of Colorado Peptide
Core Facility), 601 DNA, or the His-ATPase domain. Kd was determined byCell Reports 16, 3195–3207, September 20, 2016 3205
nonlinear least-squares analysis in Kaleidagraph using the following
equation:
Dd=Ddmax

ð½L+ ½P+KdÞ 
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
ð½L+ ½P+KdÞ2  4½P½L
q 
2½P;
where [L] is the concentration of the peptide, [P] is the concentration of the pro-
tein, Dd is the observed chemical shift change, and Ddmax is the normalized
chemical shift change at saturation. Normalized chemical shift changes were
calculated using the equation Dd=
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
ðDdHÞ2 + ðDdN=5Þ2
q
, where Dd is the
change in chemical shift in parts per million.
Crystallization and Structure Determination of MORC3-CW in
Complex with H3K4me3, H3K4me1, and H3K4me0
The MORC3 CW domain (residues 407–455) was concentrated to 15 mg/ml
and incubated on ice with H3K4me3, H3K4me1, or H3K4me0 in a 1:1.5 molar
ratio for 1 hr before crystallization. Crystals of the CW:H3K4me0 complex were
grown using the hanging-drop diffusion method at 18C by mixing equal vol-
umes of protein-peptide solution with well solution composed of 1.6M sodium
citrate (pH 6.5). Crystals of the CW:H3K4me1 and CW:H3K4me3 complexes
were grown via hanging-drop diffusion by combining equal volumes of pro-
tein-peptide solution with well solution composed of 2.5 M (NH4)2SO4 supple-
mented with 0.1 M sodium acetate. X-ray diffraction data were collected from
single crystals at 100Kon a beamline 4.2.2 at theAdvance Light Source admin-
istrated by the Molecular Biology Consortium. Datasets were integrated and
scaled using HKL2000, imosflm, and SCALA. The structures were obtained
by molecular replacement using the CW domain (PDB: 2RR4) as a search
model. Refmac and Phenix were used in the refinement, and the models
were built using Coot. The crystallographic data are summarized in Table S3.
EMSA
601 DNA and NCPs were produced as described in Klein et al. (2016).
Increasing amounts of MORC3 His-ATPase domain (1–20 molar excess)
were incubated with 601 DNA (3 pM) or with NCPs (3 pM) in 20 mM Tris-HCl
(pH 7.5) buffer, 150 mM NaCl, and 2 mM DTT for 1 hr at room temperature.
The reaction mixtures were loaded on 5% polyacrylamide gels, and electro-
phoresis was performed in 0.23 TB buffer at 150 V for 1 hr on ice. Gels
were stained with ethidium bromide and visualized with AlphaImager
(AlphaInotech).
ATPase Assays
The ATPase assays were performed using the EnzChek Phosphate Assay Kit
(Molecular Probes). The reactions were carried out on 1.5–3.0 mM of MORC3
His-ATPase or His-ATPase-CW, 3 mM ATP, in the presence and absence of
20–40 mg/ml dsDNA (14-mer, 50-GCTTTGCTGTAAGG-30; Integrated DNA
Technologies), 20 mg/ml mononucleosomes or dinucleosomes (Reaction
Biology), or 1 mM 601 DNA in a buffer containing 50 mM Tris-HCl (pH 7.5),
1 mMMgCl2, 0.1 mM sodium azide, 200 mMMESG, and 1 U of PNP. Reaction
mixtures were incubated for 20 min at 22C or 30 min at 30C, and the release
of inorganic phosphate was monitored by measuring the absorbance at
360 nm on a Nanodrop 2000c spectrophotometer (Thermo Scientific). In the
presence of inorganic phosphate, produced by the hydrolysis of ATP to
ADP, MESG is enzymatically converted to ribose 1-phosphate and MESG by
PNP, resulting in a shift in the wavelength absorbance from 330 nm for
MESG to 360 nm for the product. Error was calculated as the SD of at least
three separate experiments (two experiments for ATPase-CW with DNA or
H3 at 30C). Due to the sensitivity to inorganic phosphate, HEPES buffer
was used during purification of the proteins for this assay.
Chromatin Association Assays
The cDNA encoding full-length human MORC3 was acquired from the CCSB
Human ORFeome Collection v.5.1 and was cloned as an N-terminal 33 FLAG
fusion into pSEB-N3F (gift of Dr. Tong-Chuan He, University of Chicago).
Amino acid substitutions were introduced by QuikChange site-directed muta-
genesis (Stratagene). Asynchronously growing HeLa cells were harvested
by trypsinization 48 hr after transfection with the indicated FLAG-tagged
MORC3 constructs. Pellets were washed once with cold 13 PBS, snap-frozen3206 Cell Reports 16, 3195–3207, September 20, 2016in liquid N2, and either processed immediately or stored at 80C. Cell pellets
were resuspended in 13 volume CSK buffer (10 mM PIPES [pH 7.0], 300 mM
sucrose, 100 mM NaCl, 3 mM MgCl2, 0.1% Triton X-100, and 13 Complete
EDTA-Free protease inhibitor cocktail from Roche) and incubated on ice for
20 min. Total protein was quantified by Bradford assay (Bio-Rad), and 10%
of this total fraction was combined with an equivalent volume of CSK buffer
supplemented with Universal Nuclease (Thermo Scientific, 1:5,000). The con-
centration of the total fraction is now 0.53. The remaining cell lysate was
centrifuged at 1,300 3 g for 5 min at 4C. The supernatant (soluble fraction)
was collected. The chromatin pellet was resuspended in 13 volume CSK
buffer and kept on ice for 10 min before being spun again at 1,300 3 g for
5 min at 4C. The supernatant was discarded, and the chromatin pellet was
solubilized in CSK buffer supplemented with Universal Nuclease. From each
fraction, 1–5 mg of protein (estimated from Bradford on total extract) was
resolved by SDS-PAGE, transferred to a polyvinylidene fluoride (PVDF)
membrane (Thermo Scientific), and probed with the indicated antibodies
(FLAG, Sigma #F1804, 1:5,000; b-tubulin, Millipore #05-661, 1:5,000; H3,
Epicypher #13-0001, 1:25,000).
Immunofluorescence
Asynchronously growing HeLa cells were cultured in Nunc Lab-TeK II chamber
slides (Thermo Scientific) and transiently transfected with 33 FLAG-MORC3
transgenes using TurboFect transfection reagent (Thermo Scientific). Cells
were washed with 13 PBS 48 hr after transfection and fixed with cold
methanol at20C for 10min. Fixed cells were blocked for 30min in PBS con-
taining 1% (w/v) BSA before being labeled with an anti-FLAG antibody
(Sigma #F7435, 1:200) in PBS containing 1% BSA for 1 hr at 25C. Following
washing with PBS, cells were incubated with an Alexa Fluor 647-conjugated
secondary antibody (Life Technologies #A21245, 1:1,000) for 1 hr at 25C pro-
tected from light. Cells were washed with PBS and mounted using SlowFade
Gold Antifade mountant with DAPI (Thermo Scientific). Images were acquired
using a Nikon A1+ RSi confocal microscope using a 1003 objective following
excitation with 403 and 6,400 nm solid-state lasers.
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